Clinical Trial Update: To Evaluate the Immunogenicity and Safety of Sarilumab Administered as Monotherapy in Patients With Rheumatoid Arthritis (RA) [Phase 3]

View source ↗

Summary

This Phase 3 trial evaluated the immunogenicity and safety of sarilumab used as monotherapy in adults with rheumatoid arthritis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• Sarilumab (sarilumab)

Snippet

Sponsor: Sanofi | Conditions: Rheumatoid Arthritis | Phase 3 | Status: COMPLETED | Results posted: 2017-06-20